Valuation Perspective Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX 18:13:50 19/10/2026 BST			5-day change	1st Jan Change
2.175 ^USD	+0.23%		-13.29%	-20.55%

10-08	Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors	CI
10-08	Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	55.03	35.12	112.8	215.6	204.4	247.7	-	-
Change	-	-36.19%	221.19%	91.16%	-5.18%	21.17%	-	-
Enterprise Value (EV) ¹	55.03	35.12	112.8	-8.207	61.26	81.16	16.85	85.19
Change	-	-36.19%	221.19%	-107.28%	846.48%	32.48%	-79.24%	405.56%
P/E	-12.9x	-4.94x	-2.36x	-2.59x	-1.96x	-2.18x	-2.04x	-2.06x
PBR	-	-	-	0.78x	0.99x	1.05x	1.01x	1.18x
PEG	-	-0.1x	-0x	0.1x	-0.1x	0.1x	-0.31x	2.97x
Capitalization / Revenue	5.47x	9.89x	78.7x	148x	231x	833x	836x	758x
EV / Revenue	5.47x	9.89x	78.7x	-5.64x	69.3x	273x	56.9x	261x
EV / EBITDA	-19.1x	-	-	0.13x	-0.56x	-0.65x	-0.12x	-0.59x
EV / EBIT	-16x	-	-2.75x	0.12x	-0.54x	-0.66x	-0.12x	-0.55x
EV / FCF	-	-	-2.97x	0.11x	-0.64x	-0.89x	-0.12x	-0.66x
FCF Yield	-	-	-33.7%	886%	-155%	-112%	-828%	-151%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-0.3	-0.5	-1.7	-1.23	-1.4	-0.9963	-1.062	-1.055
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	10.05	3.552	1.434	1.454	0.884	0.2973	0.2962	0.3269
EBITDA ¹	-2.874	-	-	-64.49	-110.3	-124.5	-139	-144.5
EBIT ¹	-3.446	-	-40.94	-66.8	-113.6	-123.1	-143.8	-153.8
Net income ¹	-3.39	-	-46.51	-79.28	-103.1	-114.1	-136.5	-147
Net Debt ¹	-	-	-	-223.8	-143.2	-166.6	-230.9	-162.5
Reference price ²	3.878	2.471	4.020	3.190	2.750	2.170	2.170	2.170
Nbr of stocks (in thousands)	14,192	14,211	28,057	67,588	74,338	114,152	-	-
Announcement Date	21/09/21	01/05/23	28/03/24	26/03/25	16/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
PERSPECTIVE THERAPEUTICS, INC.	-2.18x	272.95x	-0.65x	-.--%	248M
WUXI APPTEC CO., LTD.	18.77x	6.69x	13.41x	1.58%	65B
LONZA GROUP AG	35.3x	6.27x	18.74x	0.92%	51.2B
ARGENX SE	27.56x	7.53x	23.83x	0.05%	51.19B
IQVIA HOLDINGS INC.	34.01x	3.32x	14.33x	-.--%	43.93B
BEONE MEDICINES AG	48.9x	5.59x	30.73x	-.--%	41.96B
REVOLUTION MEDICINES, INC.	-18.47x	189.62x	-19.51x	-.--%	38.14B
CELLTRION, INC.	28.97x	8.21x	21.25x	0.37%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	29.19x	6.17x	16.01x	-.--%	25.2B
GENMAB A/S	30.74x	5.69x	19.09x	-.--%	22.5B
Average	23.28x	51.21x	13.72x	0.29%	37.26B
Weighted average by Cap.	25.95x	25.17x	15.47x	0.44%